CD8A and neoplasm: Butyrate augmented oxaliplatin efficacy by enhancing the anti-tumor activity of CD8+ T cells in an IL-12 signaling pathway-dependent manner.Butyrate prompted cytotoxic CD8+ T cell anti-tumor responses in vitro and in vivo through the IL-12 signaling pathway.Clinically, responders to oxaliplatin had higher concentrations of serum butyrate compared to non-responders.